TROP2 as Patient-Tailoring but Not Prognostic Biomarker for Breast Cancer

Trophoblast cell surface antigen 2 (TROP2) has emerged as a promising target of antibody-drug conjugates (ADCs) for triple-negative breast cancer (TNBC), as well as other breast cancers (BCs). This study aims to investigate the biomarker value of TROP2 for patient-tailoring and prognostic for BC pat...

Full description

Saved in:
Bibliographic Details
Published in:OncoTargets and therapy 2022-01, Vol.15, p.509-520
Main Authors: Liu, Xiaoyue, Zhou, Tianhao, Wang, Yongmei, Pei, Min, Wang, Guifeng, Chu, Wendi, Wang, Qi, Du, Shaoqian, Wang, Hongxia, Wang, Chunhe
Format: Article
Language:English
Subjects:
Antigens
Biological products
Breast cancer
Cancer
Health aspects
Immunohistochemistry
Oncology, Experimental
Original Research
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Trophoblast cell surface antigen 2 (TROP2) has emerged as a promising target of antibody-drug conjugates (ADCs) for triple-negative breast cancer (TNBC), as well as other breast cancers (BCs). This study aims to investigate the biomarker value of TROP2 for patient-tailoring and prognostic for BC patients, including TNBC. The levels of TROP2 expression in 404 Chinese BC tissues on tissue microarrays (TMAs) were quantified by immunohistochemistry and their correlations to the clinicopathological factors and the overall survival rate were analyzed. Also, BC cell lines and patient-derived organoids (PDOs) with different TROP2 expression levels were employed to investigate the correlation between TROP2 expression levels and the therapeutic responses to DS001, a TROP2-directed ADC molecule with stable linker and potent payload. TROP2 overexpression was identified in significantly more ( = 0.046) tumor tissues (41.08%, 99/241) than normal adjacent tissues (31.29%, 51/163) from Chinese BC patients, and in significantly more ( = 0.024) TNBC patients (59.38%, 19/32) than in other BC types (38.28%, 80/209). BC cell line with the lowest TROP2 expression level failed to respond to DS001 treatment. The levels of TROP2 expression were determined to be significantly correlated with the potencies of DS001 treatment, but not with the overall survival rates of the patients. Our results demonstrated that TROP2 could serve as a patient-tailoring and predictive biomarker for ADC therapeutics but not as a general prognostic biomarker to predicate patient survival.
ISSN:1178-6930
1178-6930
DOI:10.2147/OTT.S354048